SYNTHETIC DEMONSTRATION — no real student or patient. Not a medical device.

rheumatology

Rheumatoid Arthritis Treatment Options: DMARDs and Biologics

Rheumatoid arthritis treatment aims for remission using a treat-to-target strategy. Methotrexate is the preferred first-line DMARD; biologics (TNF inhibitors, IL-6 inhibitors, others) and JAK inhibitors are added or substituted when needed. Corticosteroids manage flares but should be minimized long-term due to side effects.

Talk to a clinician

Gale can match you with a licensed clinician for a visit.

Find care →

What is the goal of RA treatment?

The primary goal of RA management is remission — or, when remission is not achievable, low disease activity. This "treat-to-target" strategy is associated with better long-term joint outcomes, less disability, and reduced cardiovascular risk 13. Treatment is adjusted regularly based on disease-activity scores until the target is reached, rather than waiting to see what happens over months.

What are conventional DMARDs?

Disease-modifying antirheumatic drugs (DMARDs) are the backbone of RA treatment 12:

Methotrexate is the preferred first-line DMARD in most patients who can tolerate it. It is taken once weekly (oral or injectable) and takes 6–8 weeks for initial effect and several months for full benefit. It requires periodic liver and blood-count monitoring. Folic acid supplementation is taken alongside it to reduce side effects.

Hydroxychloroquine is a milder DMARD often used in combination or for mild disease. Requires annual eye monitoring.

Sulfasalazine is often combined with methotrexate. Monitoring includes blood counts.

Leflunomide is an alternative when methotrexate is not tolerated.

What are biologic DMARDs?

Biologics are targeted therapies derived from biologic sources that block specific immune pathways driving RA inflammation 12:

  • TNF inhibitors (e.g., adalimumab, etanercept, infliximab): Block tumor necrosis factor, a key inflammatory signal. Most commonly used biologic class in RA.
  • IL-6 inhibitors (e.g., tocilizumab, sarilumab): Block the interleukin-6 pathway.
  • T-cell co-stimulation blocker (abatacept): Modulates T-cell activation.
  • B-cell depleter (rituximab): Depletes CD20-positive B cells; used in some cases after failure of other agents.

Biologics are given by injection or infusion and typically require screening for latent tuberculosis and hepatitis before starting. They increase infection risk and are contraindicated with some live vaccines.

What are JAK inhibitors?

JAK (Janus kinase) inhibitors are oral small-molecule targeted therapies that block intracellular signaling pathways used by multiple inflammatory cytokines 1:

  • Tofacitinib, baricitinib, upadacitinib are approved for RA in the U.S.
  • Taken as oral pills — an advantage for patients who prefer to avoid injections.
  • ACR guidelines recommend initiating these after at least one DMARD has failed 1. They carry similar infection risks to biologics, with additional signals for cardiovascular events and thrombosis at higher doses in certain patient populations — a consideration your rheumatologist will weigh against the benefits.

How does a rheumatologist choose which treatment?

Treatment choice follows a step-wise approach based on disease activity, patient comorbidities, preferences, and response to prior therapy 1:

1. Mild disease: Conventional DMARD monotherapy, typically methotrexate 2. Moderate-to-severe, or inadequate response to methotrexate: Add or switch to a biologic DMARD or JAK inhibitor — with or without continued methotrexate 3. Failure of initial biologic: Switch to a different biologic class or JAK inhibitor

The 2021 ACR guideline favors methotrexate as the first step and strongly recommends a treat-to-target approach with frequent monitoring 1.

What about pain management and other supportive treatments?

Beyond DMARDs and biologics 12:

  • NSAIDs: Help with pain and stiffness but do not modify the underlying disease; used as adjuncts, not substitutes for DMARDs.
  • Corticosteroids (prednisone): Rapid-acting anti-inflammatories used short-term during flares or as bridge therapy. Long-term use carries significant risks (bone thinning, blood sugar elevation, immune suppression) and should be minimized.
  • Physical and occupational therapy: Exercise preserves joint function; occupational therapy adapts daily activities to protect joints.
  • Cardiovascular risk management: Smoking cessation, blood pressure and cholesterol control are part of comprehensive RA care given the disease's cardiovascular impact.

What specialist treats RA?

A rheumatologist is the primary specialist for RA diagnosis, monitoring, and treatment decisions. Gale does not currently provide rheumatology as a direct specialty, but can help you organize your symptom history, prepare for a rheumatology appointment, and coordinate the care conversation with your primary clinician.

Common questions

How long does it take for RA medications to work?

Conventional DMARDs like methotrexate can take 6 to 12 weeks or longer to reach full effect. During this time, your doctor may use short-term steroids or NSAIDs for symptom control. Biologics and JAK inhibitors often show faster responses — sometimes within a few weeks.

Are RA medications safe long term?

All RA medications carry some risks, and the monitoring schedules (blood tests, eye exams, etc.) are designed to catch problems early. The risks of uncontrolled RA — progressive joint damage, disability, and cardiovascular effects — generally outweigh the risks of appropriately monitored treatment. Your rheumatologist reviews this balance with you regularly.

Can RA go into remission?

Yes. With modern treat-to-target approaches and the range of available DMARDs and biologics, clinical remission is achievable for many people with RA — particularly those who begin effective treatment early. Remission may require ongoing medication to maintain.

Do I need surgery for rheumatoid arthritis?

Most people with RA managed on effective DMARDs do not require surgery. When significant joint damage has occurred before adequate treatment, procedures such as synovectomy or joint replacement may be considered. This is a discussion with both your rheumatologist and an orthopedic surgeon if it becomes relevant.

Talk to a clinician

Gale can match you with a licensed clinician for a visit.

Find care →

Important safety considerations with RA medications

  • —Fever, chills, or signs of infection while on biologics, JAK inhibitors, or methotrexate — these medications suppress the immune system and infections can be more serious
  • —Unusual bruising, pallor, or shortness of breath (possible bone marrow effects with certain DMARDs)
  • —Significant nausea, right-sided abdominal pain, or jaundice with methotrexate
  • —Visual changes during long-term hydroxychloroquine use

If you develop a serious infection — high fever, difficulty breathing, or signs of sepsis — while on immunosuppressive therapy, seek emergency care and tell providers which medications you are taking.

This article provides general health education and does not constitute medical advice. RA treatment decisions are individualized. Never start, stop, or change RA medications without guidance from your rheumatologist.

References

  1. 1.Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, et al. (2021). 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatology. doi:10.1002/art.41752 ✓2021 ACR RA guideline: treat-to-target approach, methotrexate as preferred first-line DMARD, positioning of biologics and JAK inhibitors, and steroid minimization strategy
  2. 2.McInnes IB, Schett G (2011). The pathogenesis of rheumatoid arthritis. N Engl J Med. doi:10.1056/NEJMra1004965 ✓NEJM RA pathogenesis review: mechanistic basis for targeted biologic therapies (TNF, IL-6, B-cell, T-cell pathways) as therapeutic targets in RA
  3. 3.National Institute of Arthritis and Musculoskeletal and Skin Diseases (2024). Rheumatoid Arthritis Symptoms, Causes, & Risk Factors. NIAMS Health Topics. link ✓NIAMS patient overview: accessible description of RA treatment categories and the importance of disease-modifying therapy for long-term joint protection

3 sources, numbered by first appearance. General health information, not medical advice — synthetic demonstration content.